Molecular imaging in myeloma precursor disease

Seminars in Hematology

Volumn 48, Issue 1, 2011, Pages 22-31

  Mena, Esther ^a   Choyke, Peter ^a   Tan, Esther ^a,b   Landgren, Ola ^a   Kurdziel, Karen ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; SODIUM FLUORIDE F 18;

ANEMIA; ARTICLE; BONE LESION; BONE MARROW; BONE METASTASIS; BONE SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG CLEARANCE; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MOLECULAR IMAGING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SENSITIVITY AND SPECIFICITY; SMOLDERING MULTIPLE MYELOMA;

HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78650981723     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.11.006     Document Type: Article

References (58)

1. Landgren O., Kyle R.A., Pfeiffer R.M., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
2. Kyle R.A., Durie B.G., Rajkumar S.V., et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24:1121-1127.
3. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
4. Rajkumar S.V., Kyle R.A. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005, 80:1371-1382.
5. Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma. Cancer 1975, 36:842-854.
6. Durie B.G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006, 42:1539-1543.
7. Weber D.M., Dimopoulos M.A., Moulopoulos L.A., Delasalle K.B., Smith T., Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997, 97:810-814.
8. Blade J., Rosinol L. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Curr Treat Options Oncol 2006, 7:237-245.
9. Giuliani N., Rizzoli V., Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006, 108:3992-3996.
10. Terpos E., Sezer O., Croucher P., Dimopoulos M.A. Myeloma bone disease and proteasome inhibition therapies. Blood 2007, 110:1098-1104.
11. Collins C.D. Multiple myeloma. Cancer Imaging 2004, 4. Spec No A:S47-53.
12. Mulligan M.E. Skeletal abnormalities in multiple myeloma. Radiology 2005, 234:313-314.
13. Mahnken A.H., Wildberger J.E., Gehbauer G., et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002, 178:1429-1436.
14. Horger M., Claussen C.D., Bross-Bach U., et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol 2005, 54:289-297.
15. Hur J., Yoon C.S., Ryu Y.H., Yun M.J., Suh J.S. Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography. J Comput Assist Tomogr 2007, 31:342-347.
16. Baur-Melnyk A., Reiser M. Oncohaematologic disorders affecting the skeleton in the elderly. Radiol Clin North Am 2008, 46:785-798.
17. Mahnken A.H., Wildberger J.E., Gehbauer G., et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002, 178:1429-1436.
18. Horger M., Claussen C.D., Bross-Bach U., et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol 2005, 54:289-297.
19. Ghanem N., Lohrmann C., Engelhardt M., et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 2006, 16:1005-1014.
20. Mirowitz S.A., Apicella P., Reinus W.R., Hammerman A.M. MR imaging of bone marrow lesions: relative conspicuousness on T1-weighted, fat-suppressed T2-weighted, and STIR images. AJR Am J Roentgenol 1994, 162:215-221.
21. Ghanem N., Lohrmann C., Engelhardt M., et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 2006, 16:1005-1014.
22. Baur-Melnyk A., Buhmann S., Becker C., et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 2008, 190:1097-1104.
23. Walker R., Barlogie B., Haessler J., et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007, 25:1121-1128.
24. Baur A., Stäbler A., Bartl R., Lamerz R., Reiser M. Infiltration patterns of plasmacytomas in magnetic resonance tomography [in German]. Rofo 1996, 164:457-463.
25. Baur A., Stäbler A., Nagel D., et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?. Cancer 2002, 95:1334-1345.
26. Pepe J., Petrucci M.T., Nofroni I., et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol 2006, 134:485-490.
27. Bellaiche L., Laredo J.D., Liote F., et al. Magnetic resonance appearance of monoclonal gammopathies of unknown significance and multiple myeloma. The GRI Study Group. Spine 1997, 22:2551-2557.
28. Vande Berg B.C., Michaux L., Lecouvet F.E., et al. Nonmyelomatous monoclonal gammopathy: correlation of bone marrow MR images with laboratory findings and spontaneous clinical outcome. Radiology 1997, 202:247-251.
29. Moulopoulos L.A., Dimopoulos M.A., Smith T.L., et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995, 13:251-256.
30. Wang M., Alexanian R., Delasalle K., Weber D. Abnormal MRI of spine is the dominant risk factor for early progression of asymptomatic multiple myeloma [abstract]. Blood 2003, 102:687a.
31. Morgan B., Thomas A.L., Drevs J., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003, 21:3955-3964.
32. Hillengass J., Wasser K., Delorme S., et al. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res 2007, 13:475-481.
33. Munshi N.C., Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001, 28:565-569.
34. Hillengass J., Zechmann C., Bäuerle T., et al. Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res 2009, 15:3118-3125.
35. Woolfenden J.M., Pitt M.J., Durie B.G., Moon T.E. Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology 1980, 134:723-728.
36. Chiu M.L., Kronauge J.F., Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 1990, 31:1646-1653.
37. Mele A., Offidani M., Visani G., et al. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. Br J Haematol 2007, 136:729-735.
38. Alexandrakis M.G., Kyriakou D.S., Passam F.H., Malliaraki N., Christophoridou A.V., Karkavitsas N. Correlation between the uptake of Tc99m-sestamibi and prognostic factors in patients with multiple myeloma. Clin Lab Hematol 2002, 24:155-159.
39. Villa G., Balleari E., Carletto M., et al. Staging and therapy monitoring of multiple myeloma by 99mTc-sestamibi scintigraphy: a five year single center experience. J Exp Clin Cancer Res 2005, 24:355-361.
40. Durie B.G., Waxman A.D., D'Agnolo A., Williams C.M. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002, 43:1457-1463.
41. Durie B.G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006, 42:1539-1543.
42. Schirrmeister H., Bommer M., Buck A.K., et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002, 29:361-366.
43. Bredella M.A., Steinbach L., Caputo G., Segall G., Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005, 184:1199-1204.
44. Shortt C.P., Gleeson T.G., Breen K.A., et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 2009, 192:980-986.
45. Fonti R., Salvatore B., Quarantelli M., et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 2008, 49:195-200.
46. Blau M., Ganatra R., Bender M.A. 18F-fluoride for bone imaging. Semin Nucl Med 1972, 2:31-37.
47. Schirrmeister H., Glatting G., Hetzel J., et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001, 42:1800-1804.
48. Cook G.J., Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med 2001, 31:50-61.
49. Even-Sapir E., Metser U., Mishani E., Lievshitz G., Lerman H., Leibovitch I. The detection of bone metastases in patients with high- risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006, 47:287-297.
50. Blake G.M., Park-Holohan S.J., Cook G.J., Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med 2001, 31:28-49.
51. Fenchel M., Konaktchieva M., Weisel K., Kraus S., Claussen C.D., Horger M. Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging a feasibility study. Acad Radiol 2010 Sep 1, [Epub ahead of print].
52. Agool A., Schot B., Jager P., Vellenga E. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med 2006, 47:1592-1598.
53. Dankerl A., Liebisch P., Glatting G., et al. Multiple myeloma: molecular imaging with 11C-methionine PET/CT: initial experience. Radiology 2007, 242:498-508.
54. Kenny L.M., Coombes R.C., Oulie I., et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008, 49:879-886.
55. Morrison M.S., Ricketts S.A., Barnett J., Cuthbertson A., Tessier J., Wedge S.R. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 2009, 50:116-122.
56. Beaulieu V., Da Silva N., Pastor-Soler N., et al. Modulation of the actin cytoskeleton via gelsolin regulates vacuolar H+-ATPase recycling. J Biol Chem 2005, 280:8452-8463.
57. Nanni C., Zamagni E., Cavo M., et al. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol 2007, 5:68-75.
58. Nishizawa M., Nakamoto Y., Suga T., Kitano T., Ishikawa T., Yamashita K. 11C-methionine PET/CT for multiple myeloma. Int J Hematol 2010, 91:733-734.